CR20190156A - Derivados de bipirazol como inhibidores jak - Google Patents
Derivados de bipirazol como inhibidores jakInfo
- Publication number
- CR20190156A CR20190156A CR20190156A CR20190156A CR20190156A CR 20190156 A CR20190156 A CR 20190156A CR 20190156 A CR20190156 A CR 20190156A CR 20190156 A CR20190156 A CR 20190156A CR 20190156 A CR20190156 A CR 20190156A
- Authority
- CR
- Costa Rica
- Prior art keywords
- jak
- activity
- jak inhibitors
- diseases
- cancer
- Prior art date
Links
- YGAILVDTGIMZAB-UHFFFAOYSA-N 3-pyrazol-3-ylidenepyrazole Chemical class N1=NC=CC1=C1N=NC=C1 YGAILVDTGIMZAB-UHFFFAOYSA-N 0.000 title 1
- 229940122245 Janus kinase inhibitor Drugs 0.000 title 1
- 102000015617 Janus Kinases Human genes 0.000 abstract 6
- 108010024121 Janus Kinases Proteins 0.000 abstract 6
- 201000010099 disease Diseases 0.000 abstract 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 4
- 230000000694 effects Effects 0.000 abstract 4
- 208000023275 Autoimmune disease Diseases 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 201000011510 cancer Diseases 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000027866 inflammatory disease Diseases 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
- A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Transplantation (AREA)
- Epidemiology (AREA)
- Rheumatology (AREA)
- Physical Education & Sports Medicine (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Pain & Pain Management (AREA)
- Biotechnology (AREA)
- Dermatology (AREA)
- AIDS & HIV (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La presente invención proporciona compuestos de la Fórmula I: o sales farmacéuticamente aceptables de este, así como sus composiciones y métodos de uso, que inhiben la actividad de la Janus quinasa (JAK) y son útiles en el tratamiento de enfermedades relacionadas con la actividad de JAK, que incluyen, por ejemplo, trastornos inflamatorios, trastornos autoinmunitarios, cáncer, y otras enfermedades.The present invention provides compounds of Formula I: or pharmaceutically acceptable salts thereof, as well as their compositions and methods of use, that inhibit the activity of Janus kinase (JAK) and are useful in the treatment of diseases related to the activity of JAK including, for example, inflammatory disorders, autoimmune disorders, cancer, and other diseases.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361824683P | 2013-05-17 | 2013-05-17 | |
| PCT/US2014/038388 WO2014186706A1 (en) | 2013-05-17 | 2014-05-16 | Bipyrazole derivatives as jak inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CR20190156A true CR20190156A (es) | 2019-05-16 |
Family
ID=50983151
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20190156A CR20190156A (es) | 2013-05-17 | 2014-05-16 | Derivados de bipirazol como inhibidores jak |
| CR20150633A CR20150633A (es) | 2013-05-17 | 2015-12-03 | Derivados del bipirazol como inhibidores jak |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CR20150633A CR20150633A (es) | 2013-05-17 | 2015-12-03 | Derivados del bipirazol como inhibidores jak |
Country Status (36)
| Country | Link |
|---|---|
| US (8) | US9382231B2 (es) |
| EP (6) | EP3231801B1 (es) |
| JP (5) | JP6415543B2 (es) |
| KR (4) | KR102442747B1 (es) |
| CN (2) | CN105452239B (es) |
| AR (2) | AR096330A1 (es) |
| AU (5) | AU2014265279B2 (es) |
| BR (1) | BR112015028501B8 (es) |
| CA (1) | CA2911536C (es) |
| CL (1) | CL2015003355A1 (es) |
| CR (2) | CR20190156A (es) |
| CY (3) | CY1119105T1 (es) |
| DK (4) | DK4275756T3 (es) |
| EA (2) | EA036448B1 (es) |
| ES (5) | ES2626793T3 (es) |
| FI (2) | FI3786162T3 (es) |
| HK (1) | HK1245769B (es) |
| HR (5) | HRP20251220T1 (es) |
| HU (5) | HUE053122T2 (es) |
| IL (4) | IL242453B (es) |
| LT (5) | LT2997023T (es) |
| ME (2) | ME02763B (es) |
| MX (2) | MX373238B (es) |
| MY (1) | MY174788A (es) |
| PE (2) | PE20160126A1 (es) |
| PH (2) | PH12015502563B1 (es) |
| PL (5) | PL3527263T3 (es) |
| PT (5) | PT2997023T (es) |
| RS (5) | RS67392B1 (es) |
| SG (2) | SG11201509180WA (es) |
| SI (5) | SI3786162T1 (es) |
| SM (5) | SMT201700258T1 (es) |
| TR (1) | TR201905814T4 (es) |
| TW (4) | TWI664176B (es) |
| UA (1) | UA117830C2 (es) |
| WO (1) | WO2014186706A1 (es) |
Families Citing this family (79)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| EP2740731B1 (en) | 2007-06-13 | 2016-03-23 | Incyte Holdings Corporation | Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| BRPI1012108B8 (pt) | 2009-05-22 | 2021-05-25 | Incyte Corp | composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico |
| NZ596479A (en) | 2009-05-22 | 2014-01-31 | Incyte Corp | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| EP2448938B9 (en) | 2009-06-29 | 2015-06-10 | Incyte Corporation | Pyrimidinones as pi3k inhibitors |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| CA2792508C (en) | 2010-03-10 | 2018-01-16 | Incyte Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| EA202091303A3 (ru) | 2010-05-21 | 2021-05-31 | Инсайт Холдингс Корпорейшн | Композиция ингибитора jak для местного применения |
| CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| JP5961187B2 (ja) | 2010-12-20 | 2016-08-02 | インサイト・ホールディングス・コーポレイションIncyte Holdings Corporation | Pi3k阻害剤としてのn−(1−(置換フェニル)エチル)−9h−プリン−6−アミン |
| US8691807B2 (en) | 2011-06-20 | 2014-04-08 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
| MX389479B (es) | 2011-09-02 | 2025-03-20 | Incyte Holdings Corp | Heterociclilaminas como inhibidores de fosfoinositida 3-cinasas (pi3k) |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| CA2888816A1 (en) | 2012-11-01 | 2014-05-08 | Incyte Corporation | Tricyclic fused thiophene derivatives as jak inhibitors |
| KR102242077B1 (ko) | 2012-11-15 | 2021-04-20 | 인사이트 홀딩스 코포레이션 | 룩솔리티니브의 서방성 제형 |
| EP3489239B1 (en) | 2013-03-06 | 2021-09-15 | Incyte Holdings Corporation | Processes and intermediates for making a jak inhibitor |
| CR20190156A (es) * | 2013-05-17 | 2019-05-16 | Incyte Corp | Derivados de bipirazol como inhibidores jak |
| MX376856B (es) | 2013-08-07 | 2025-03-07 | Incyte Holdings Corp | Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1). |
| SG11201607083VA (en) * | 2014-02-28 | 2016-09-29 | Incyte Corp | Jak1 inhibitors for the treatment of myelodysplastic syndromes |
| CA3158254C (en) | 2014-04-08 | 2024-05-21 | Incyte Corporation | Treatment of b-cell malignancies by a combination jak and pi3k inhibitors |
| SG11201609016VA (en) | 2014-04-30 | 2016-11-29 | Incyte Corp | Processes of preparing a jak1 inhibitor and new forms thereto |
| WO2015184305A1 (en) * | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| US10077277B2 (en) | 2014-06-11 | 2018-09-18 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as PI3K inhibitors |
| US9421199B2 (en) | 2014-06-24 | 2016-08-23 | Sydnexis, Inc. | Ophthalmic composition |
| WO2016172712A2 (en) | 2015-04-23 | 2016-10-27 | Sydnexis, Inc. | Ophthalmic composition |
| WO2016130501A1 (en) | 2015-02-09 | 2016-08-18 | Incyte Corporation | Aza-heteroaryl compounds as pi3k-gamma inhibitors |
| SG10201912302VA (en) | 2015-02-27 | 2020-02-27 | Incyte Corp | Salts of pi3k inhibitor and processes for their preparation |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| WO2016183060A1 (en) | 2015-05-11 | 2016-11-17 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| US11052094B2 (en) * | 2015-05-29 | 2021-07-06 | Sydnexis, Inc. | D2O stabilized pharmaceutical formulations |
| RS63359B1 (sr) | 2015-11-06 | 2022-07-29 | Incyte Corp | Heterociklična jedinjenja kao inhibitori pi3k-gama |
| ES2995198T3 (en) | 2016-01-05 | 2025-02-07 | Incyte Corp | Pyridine compounds as pi3k-gamma inhibitors |
| TW201803871A (zh) | 2016-06-24 | 2018-02-01 | 英塞特公司 | 作為PI3K-γ抑制劑之雜環化合物 |
| CN107759623B (zh) * | 2016-08-23 | 2020-08-14 | 苏州旺山旺水生物医药有限公司 | Jak抑制剂的中间体及其制备方法 |
| BR112019004486A2 (pt) * | 2016-09-06 | 2019-05-28 | F.Hoffmann-La Roche Ag | compostos de 8-(azetidin-1-il)-[1,2,4] triazolo [1,5a] piridinil, composições e métodos de uso dos mesmos |
| KR102717072B1 (ko) | 2017-10-18 | 2024-10-15 | 인사이트 코포레이션 | Pi3k-감마 저해제로서의 3차 하이드록시기로 치환된 축합된 이미다졸 유도체 |
| TW201924683A (zh) | 2017-12-08 | 2019-07-01 | 美商英塞特公司 | 用於治療骨髓增生性贅瘤的低劑量組合療法 |
| MD3746429T2 (ro) | 2018-01-30 | 2022-08-31 | Incyte Corp | Procedee pentru prepararea de (1-(3-fluoro-2-(trifluorometil)izonicotinil)piperidin-4-onă) |
| CA3091339A1 (en) | 2018-02-16 | 2019-08-22 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of cytokine-related disorders |
| WO2019191679A1 (en) | 2018-03-30 | 2019-10-03 | Incyte Corporation | Biomarkers for inflammatory skin disease |
| KR20260080448A (ko) | 2018-03-30 | 2026-06-02 | 인사이트 코포레이션 | Jak 억제제를 사용하는 화농성 한선염의 치료 |
| CN112567247A (zh) | 2018-04-13 | 2021-03-26 | 因赛特公司 | 用于移植物抗宿主病的生物标志物 |
| CN108484468A (zh) * | 2018-05-11 | 2018-09-04 | 南京大学 | 芳基氮杂环丁烷类化合物的制备方法 |
| IL278889B2 (en) | 2018-06-01 | 2025-11-01 | Incyte Corp | Dosing regimen for the treatment of pi3k related disorders |
| CR20250050A (es) | 2018-09-05 | 2025-03-19 | Incyte Corp | Formas cristalinas de un inhibidor de fosfoinositida 3–quinasa (pi3k) (divisional 2021-0165) |
| KR20210109522A (ko) | 2018-10-31 | 2021-09-06 | 인사이트 코포레이션 | 혈액 질환의 치료를 위한 병용 요법 |
| US11596632B2 (en) | 2018-12-19 | 2023-03-07 | Incyte Corporation | JAK1 pathway inhibitors for the treatment of gastrointestinal disease |
| UA130579C2 (uk) * | 2019-03-05 | 2026-03-25 | Інсайт Корпорейшн | Інгібітори шляхів jak1 для лікування хронічної дисфункції алотрансплантата легень |
| US11624751B2 (en) | 2019-03-19 | 2023-04-11 | Incyte Corporation | Biomarkers for vitiligo |
| CA3129665A1 (en) | 2019-03-21 | 2020-09-24 | Onxeo | A dbait molecule in combination with kinase inhibitor for the treatment of cancer |
| CA3156007A1 (en) | 2019-09-27 | 2021-04-01 | Disc Medicine, Inc. | METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS |
| WO2021072116A1 (en) | 2019-10-10 | 2021-04-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| US12360120B2 (en) | 2019-10-10 | 2025-07-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| JP7518900B2 (ja) * | 2019-10-16 | 2024-07-18 | インサイト・コーポレイション | 皮膚エリテマトーデス及び扁平苔癬(lp)の治療のためのjak1阻害剤の使用 |
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| KR20220098759A (ko) | 2019-11-08 | 2022-07-12 | 인쎄름 (엥스띠뛰 나씨오날 드 라 쌍떼 에 드 라 흐쉐르슈 메디깔) | 키나제 억제제에 대해 내성을 획득한 암의 치료 방법 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| AU2021273014A1 (en) | 2020-05-13 | 2022-11-17 | AbbVie Deutschland GmbH & Co. KG | Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease |
| ES3075793T3 (en) | 2020-05-13 | 2026-08-07 | Disc Medicine Inc | Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis |
| SI4157831T1 (sl) * | 2020-06-02 | 2025-02-28 | Incyte Corporation | Postopki za pripravo zaviralca jak1 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| IL300555A (en) | 2020-08-18 | 2023-04-01 | Incyte Corp | Process and intermediates for preparing a JAK inhibitor |
| CA3192055A1 (en) | 2020-08-18 | 2022-02-24 | Incyte Corporation | Process and intermediates for preparing a jak1 inhibitor |
| CN112159394B (zh) * | 2020-10-09 | 2021-10-22 | 嘉兴特科罗生物科技有限公司 | 一种作为jak激酶抑制剂的小分子化合物及其用途 |
| PT4255442T (pt) | 2020-12-04 | 2025-05-19 | Incyte Corp | Inibidor de jak com um análogo da vitamina d para o tratamento de doenças da pele |
| IL303238A (en) * | 2020-12-08 | 2023-07-01 | Incyte Corp | Jak1 pathway inhibitors for the treatment of vitiligo |
| TW202241439A (zh) * | 2020-12-29 | 2022-11-01 | 大陸商上海岸闊醫藥科技有限公司 | 治療與抗腫瘤劑相關的皮膚疾病或病症的試劑和方法 |
| CN112933095A (zh) * | 2020-12-29 | 2021-06-11 | 上海岸阔医药科技有限公司 | 预防或治疗egfr功能异常相关的副作用的方法 |
| CA3207859A1 (en) | 2021-01-11 | 2022-07-14 | Incyte Corporation | Combination therapy comprising jak pathway inhibitor and rock inhibitor |
| AU2022270072A1 (en) | 2021-05-03 | 2023-11-02 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of prurigo nodularis |
| CA3226714A1 (en) | 2021-07-12 | 2023-01-19 | Incyte Corporation | Process and intermediates for preparing baricitinib |
| TW202419088A (zh) | 2022-08-05 | 2024-05-16 | 美商英塞特公司 | 使用jak抑制劑之蕁麻疹治療 |
| KR20250174908A (ko) | 2023-03-16 | 2025-12-15 | 인사이트 코포레이션 | 천식의 치료를 위한 jak1 경로 저해제 |
| CN117186078A (zh) * | 2023-11-06 | 2023-12-08 | 药康众拓(北京)医药科技有限公司 | 氘代氮杂环丁烷类jak抑制剂药物及用途 |
| TW202544045A (zh) | 2024-04-22 | 2025-11-16 | 美商英塞特公司 | 抗群落刺激因子1受體抗體與jak抑制劑之組合療法 |
| US20260060987A1 (en) | 2024-09-03 | 2026-03-05 | Incyte Corporation | Methods and compositions for radioprotection and mitigation of radiation-induced injury using kinase inhibitors |
Family Cites Families (59)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS60106847U (ja) | 1983-12-27 | 1985-07-20 | 富士重工業株式会社 | 室外後写鏡 |
| JP2650681B2 (ja) | 1987-07-10 | 1997-09-03 | 株式会社ブリヂストン | 空気ばね |
| JPH0515775Y2 (es) | 1987-07-13 | 1993-04-26 | ||
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| ES2342240T3 (es) | 1998-08-11 | 2010-07-02 | Novartis Ag | Derivados de isoquinolina con actividad que inhibe la angiogenia. |
| US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| EP1294358B1 (en) | 2000-06-28 | 2004-08-18 | Smithkline Beecham Plc | Wet milling process |
| CN100391958C (zh) | 2001-09-19 | 2008-06-04 | 安万特医药股份有限公司 | 化合物 |
| PT1441737E (pt) | 2001-10-30 | 2006-12-29 | Dana Farber Cancer Inst Inc | Derivados de estrutura como inibidores da actividade do receptor de tirosina cinase flt3 |
| PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| AR042052A1 (es) | 2002-11-15 | 2005-06-08 | Vertex Pharma | Diaminotriazoles utiles como inhibidores de proteinquinasas |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| PE20050952A1 (es) | 2003-09-24 | 2005-12-19 | Novartis Ag | Derivados de isoquinolina como inhibidores de b-raf |
| RU2007123675A (ru) | 2004-11-24 | 2008-12-27 | Новартис АГ (CH) | Комбинации ингибиторов jak |
| HUE028588T2 (hu) | 2005-12-13 | 2016-12-28 | Incyte Holdings Corp | Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok |
| EP2740731B1 (en) | 2007-06-13 | 2016-03-23 | Incyte Holdings Corporation | Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| EA020777B1 (ru) * | 2007-11-16 | 2015-01-30 | Инсайт Корпорейшн | 4-пиразолил-n-арилпиримидин-2-амины, 4-пиразолил-n-пиразолилпиримидин-2-амины и 4-пиразолил-n-пиридилпиримидин-2-амины в качестве ингибиторов киназ janus |
| MY165582A (en) * | 2008-03-11 | 2018-04-05 | Incyte Holdings Corp | Azetidine and cyclobutane derivatives as jak inhibitors |
| CL2009001884A1 (es) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| WO2010083283A2 (en) | 2009-01-15 | 2010-07-22 | Incyte Corporation | Processes for preparing jak inhibitors and related intermediate compounds |
| BRPI1012108B8 (pt) | 2009-05-22 | 2021-05-25 | Incyte Corp | composto 3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il]octa no- ou heptano-nitrila, sua composição, seus usos e processo para preparar um sal de ácido fosfórico |
| NZ596479A (en) * | 2009-05-22 | 2014-01-31 | Incyte Corp | N-(hetero)aryl-pyrrolidine derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines and pyrrol-3-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| TW201113285A (en) * | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| EA021478B1 (ru) | 2009-10-09 | 2015-06-30 | Инсайт Корпорейшн | ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА |
| US20110207754A1 (en) | 2010-02-18 | 2011-08-25 | Incyte Corporation | Cyclobutane and methylcyclobutane derivatives as janus kinase inhibitors |
| CA2792508C (en) | 2010-03-10 | 2018-01-16 | Incyte Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| KR20130094710A (ko) * | 2010-04-14 | 2013-08-26 | 어레이 바이오파마 인크. | Jak 키나아제의 억제제로서 5,7-치환된-이미다조[1,2-c]피리미딘 |
| EA202091303A3 (ru) | 2010-05-21 | 2021-05-31 | Инсайт Холдингс Корпорейшн | Композиция ингибитора jak для местного применения |
| ES2536415T3 (es) | 2010-11-19 | 2015-05-25 | Incyte Corporation | Pirrolopiridinas y pirrolopirimidinas sustituidas heterocíclicas como inhibidores de JAK |
| CA2818542A1 (en) | 2010-11-19 | 2012-05-24 | Incyte Corporation | Cyclobutyl substituted pyrrolopyridine and pyrrolopyrimidine derivatives as jak inhibitors |
| WO2012076063A1 (en) * | 2010-12-10 | 2012-06-14 | Rottapharm S.P.A. | Pyridine amide derivatives as ep4 receptor antagonists |
| EP2678686B1 (en) | 2011-02-24 | 2017-10-11 | Massachusetts Institute of Technology | ALTERNATIVELY SPLICED mRNA ISOFORMS AS PROGNOSTIC INDICATORS FOR METASTATIC CANCER |
| US8691807B2 (en) * | 2011-06-20 | 2014-04-08 | Incyte Corporation | Azetidinyl phenyl, pyridyl or pyrazinyl carboxamide derivatives as JAK inhibitors |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為jak抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) * | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| AU2012312303B2 (en) | 2011-09-22 | 2016-09-15 | Merck Sharp & Dohme Corp. | Cyanomethylpyrazole carboxamides as janus kinase inhibitors |
| TW201406761A (zh) * | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲jak抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| CA2888816A1 (en) | 2012-11-01 | 2014-05-08 | Incyte Corporation | Tricyclic fused thiophene derivatives as jak inhibitors |
| KR102242077B1 (ko) | 2012-11-15 | 2021-04-20 | 인사이트 홀딩스 코포레이션 | 룩솔리티니브의 서방성 제형 |
| EP3489239B1 (en) | 2013-03-06 | 2021-09-15 | Incyte Holdings Corporation | Processes and intermediates for making a jak inhibitor |
| PE20151951A1 (es) | 2013-05-17 | 2015-12-26 | Hoffmann La Roche | Heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b |
| US9371282B2 (en) | 2013-05-17 | 2016-06-21 | Centrexion Therapeutics Corporation | Somatostatin receptor subtype 4 (SSTR4) agonists |
| TW202126620A (zh) | 2013-05-17 | 2021-07-16 | 愛爾蘭商健生科學愛爾蘭無限公司 | 胺磺醯基吡咯醯胺衍生物及其作為用於治療b型肝炎藥物的用途 |
| CR20190156A (es) * | 2013-05-17 | 2019-05-16 | Incyte Corp | Derivados de bipirazol como inhibidores jak |
| EP2803668A1 (en) | 2013-05-17 | 2014-11-19 | Boehringer Ingelheim International Gmbh | Novel (cyano-dimethyl-methyl)-isoxazoles and -[1,3,4]thiadiazoles |
| MX376856B (es) | 2013-08-07 | 2025-03-07 | Incyte Holdings Corp | Formas de dosificacion de liberacion prolongada para un inhibidor de jak 1 (cinasa de janus 1). |
| SG11201607083VA (en) | 2014-02-28 | 2016-09-29 | Incyte Corp | Jak1 inhibitors for the treatment of myelodysplastic syndromes |
| SG11201609016VA (en) | 2014-04-30 | 2016-11-29 | Incyte Corp | Processes of preparing a jak1 inhibitor and new forms thereto |
| WO2015184305A1 (en) | 2014-05-30 | 2015-12-03 | Incyte Corporation | TREATMENT OF CHRONIC NEUTROPHILIC LEUKEMIA (CNL) AND ATYPICAL CHRONIC MYELOID LEUKEMIA (aCML) BY INHIBITORS OF JAK1 |
| HUE047225T2 (hu) | 2014-12-16 | 2020-04-28 | Novartis Ag | LpxC inhibitor izoxazol hidroxámsav-vegyületek |
| CA3091339A1 (en) | 2018-02-16 | 2019-08-22 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of cytokine-related disorders |
| SI4157831T1 (sl) | 2020-06-02 | 2025-02-28 | Incyte Corporation | Postopki za pripravo zaviralca jak1 |
| PT4255442T (pt) | 2020-12-04 | 2025-05-19 | Incyte Corp | Inibidor de jak com um análogo da vitamina d para o tratamento de doenças da pele |
| IL303238A (en) | 2020-12-08 | 2023-07-01 | Incyte Corp | Jak1 pathway inhibitors for the treatment of vitiligo |
-
2014
- 2014-05-16 CR CR20190156A patent/CR20190156A/es unknown
- 2014-05-16 EP EP17158350.3A patent/EP3231801B1/en active Active
- 2014-05-16 PT PT147327050T patent/PT2997023T/pt unknown
- 2014-05-16 ES ES14732705.0T patent/ES2626793T3/es active Active
- 2014-05-16 ES ES18215671T patent/ES2845210T3/es active Active
- 2014-05-16 PL PL18215671T patent/PL3527263T3/pl unknown
- 2014-05-16 RS RS20251023A patent/RS67392B1/sr unknown
- 2014-05-16 JP JP2016514126A patent/JP6415543B2/ja active Active
- 2014-05-16 MY MYPI2015002767A patent/MY174788A/en unknown
- 2014-05-16 EA EA201592199A patent/EA036448B1/ru unknown
- 2014-05-16 LT LTEP14732705.0T patent/LT2997023T/lt unknown
- 2014-05-16 SI SI201432046T patent/SI3786162T1/sl unknown
- 2014-05-16 SI SI201431118T patent/SI3231801T1/sl unknown
- 2014-05-16 UA UAA201512465A patent/UA117830C2/uk unknown
- 2014-05-16 PT PT182156711T patent/PT3527263T/pt unknown
- 2014-05-16 PT PT202015939T patent/PT3786162T/pt unknown
- 2014-05-16 CN CN201480032106.8A patent/CN105452239B/zh active Active
- 2014-05-16 LT LTEP17158350.3T patent/LT3231801T/lt unknown
- 2014-05-16 SI SI201432117T patent/SI4275756T1/sl unknown
- 2014-05-16 MX MX2015015738A patent/MX373238B/es active IP Right Grant
- 2014-05-16 SI SI201430239A patent/SI2997023T1/sl unknown
- 2014-05-16 ES ES23185889T patent/ES3047826T3/es active Active
- 2014-05-16 RS RS20230782A patent/RS64591B1/sr unknown
- 2014-05-16 PE PE2015002406A patent/PE20160126A1/es unknown
- 2014-05-16 ME MEP-2017-116A patent/ME02763B/me unknown
- 2014-05-16 SI SI201431754T patent/SI3527263T1/sl unknown
- 2014-05-16 PL PL20201593.9T patent/PL3786162T3/pl unknown
- 2014-05-16 EP EP23185889.5A patent/EP4275756B1/en active Active
- 2014-05-16 PE PE2020000001A patent/PE20200527A1/es unknown
- 2014-05-16 TW TW103117400A patent/TWI664176B/zh active
- 2014-05-16 DK DK23185889.5T patent/DK4275756T3/da active
- 2014-05-16 KR KR1020217030190A patent/KR102442747B1/ko active Active
- 2014-05-16 EP EP14732705.0A patent/EP2997023B9/en active Active
- 2014-05-16 CN CN201711000293.3A patent/CN107698569B/zh active Active
- 2014-05-16 HU HUE18215671A patent/HUE053122T2/hu unknown
- 2014-05-16 HU HUE17158350A patent/HUE043573T2/hu unknown
- 2014-05-16 DK DK20201593.9T patent/DK3786162T3/da active
- 2014-05-16 PL PL14732705T patent/PL2997023T3/pl unknown
- 2014-05-16 AR ARP140101971A patent/AR096330A1/es active IP Right Grant
- 2014-05-16 SM SM20170258T patent/SMT201700258T1/it unknown
- 2014-05-16 PL PL17158350T patent/PL3231801T3/pl unknown
- 2014-05-16 RS RS20170526A patent/RS56012B1/sr unknown
- 2014-05-16 HR HRP20251220TT patent/HRP20251220T1/hr unknown
- 2014-05-16 SM SM20230352T patent/SMT202300352T1/it unknown
- 2014-05-16 DK DK17158350.3T patent/DK3231801T3/en active
- 2014-05-16 SM SM20190223T patent/SMT201900223T1/it unknown
- 2014-05-16 PT PT17158350T patent/PT3231801T/pt unknown
- 2014-05-16 TW TW112149597A patent/TWI885650B/zh active
- 2014-05-16 EP EP25180368.0A patent/EP4620528A3/en active Pending
- 2014-05-16 HU HUE20201593A patent/HUE063817T2/hu unknown
- 2014-05-16 HR HRP20170795TT patent/HRP20170795T1/hr unknown
- 2014-05-16 FI FIEP20201593.9T patent/FI3786162T3/fi active
- 2014-05-16 SM SM20210040T patent/SMT202100040T1/it unknown
- 2014-05-16 RS RS20210074A patent/RS61482B1/sr unknown
- 2014-05-16 US US14/279,929 patent/US9382231B2/en active Active
- 2014-05-16 KR KR1020247014111A patent/KR102729910B1/ko active Active
- 2014-05-16 DK DK18215671.1T patent/DK3527263T3/da active
- 2014-05-16 EP EP20201593.9A patent/EP3786162B1/en active Active
- 2014-05-16 BR BR112015028501A patent/BR112015028501B8/pt active IP Right Grant
- 2014-05-16 ME MEP-2019-79A patent/ME03355B/me unknown
- 2014-05-16 SG SG11201509180WA patent/SG11201509180WA/en unknown
- 2014-05-16 LT LTEP18215671.1T patent/LT3527263T/lt unknown
- 2014-05-16 TW TW108103947A patent/TWI719401B/zh active
- 2014-05-16 LT LTEP20201593.9T patent/LT3786162T/lt unknown
- 2014-05-16 ES ES17158350T patent/ES2720073T3/es active Active
- 2014-05-16 HR HRP20231048TT patent/HRP20231048T1/hr unknown
- 2014-05-16 EP EP18215671.1A patent/EP3527263B1/en active Active
- 2014-05-16 ES ES20201593T patent/ES2960731T3/es active Active
- 2014-05-16 RS RS20190315A patent/RS58743B1/sr unknown
- 2014-05-16 TR TR2019/05814T patent/TR201905814T4/tr unknown
- 2014-05-16 LT LTEP23185889.5T patent/LT4275756T/lt unknown
- 2014-05-16 WO PCT/US2014/038388 patent/WO2014186706A1/en not_active Ceased
- 2014-05-16 KR KR1020157035750A patent/KR102341908B1/ko active Active
- 2014-05-16 MX MX2020004506A patent/MX385187B/es unknown
- 2014-05-16 HU HUE23185889A patent/HUE073609T2/hu unknown
- 2014-05-16 CA CA2911536A patent/CA2911536C/en active Active
- 2014-05-16 TW TW110101630A patent/TWI840646B/zh active
- 2014-05-16 FI FIEP23185889.5T patent/FI4275756T3/fi active
- 2014-05-16 PT PT231858895T patent/PT4275756T/pt unknown
- 2014-05-16 HU HUE14732705A patent/HUE033587T2/hu unknown
- 2014-05-16 SG SG10201709469SA patent/SG10201709469SA/en unknown
- 2014-05-16 SM SM20250397T patent/SMT202500397T1/it unknown
- 2014-05-16 KR KR1020227030853A patent/KR102663357B1/ko active Active
- 2014-05-16 AU AU2014265279A patent/AU2014265279B2/en active Active
- 2014-05-16 PL PL23185889.5T patent/PL4275756T3/pl unknown
- 2014-05-16 EA EA202090291A patent/EA039660B1/ru unknown
-
2015
- 2015-11-04 IL IL24245315A patent/IL242453B/en active IP Right Grant
- 2015-11-12 PH PH12015502563A patent/PH12015502563B1/en unknown
- 2015-11-13 CL CL2015003355A patent/CL2015003355A1/es unknown
- 2015-12-03 CR CR20150633A patent/CR20150633A/es unknown
-
2016
- 2016-06-20 US US15/187,296 patent/US9926301B2/en active Active
-
2017
- 2017-06-08 CY CY20171100610T patent/CY1119105T1/el unknown
-
2018
- 2018-02-15 US US15/897,598 patent/US10435392B2/en active Active
- 2018-04-18 HK HK18105021.2A patent/HK1245769B/en unknown
- 2018-08-31 AU AU2018223058A patent/AU2018223058B2/en active Active
- 2018-10-02 JP JP2018187613A patent/JP6775560B2/ja active Active
- 2018-10-02 PH PH12018502125A patent/PH12018502125A1/en unknown
-
2019
- 2019-01-22 IL IL264409A patent/IL264409B/en active IP Right Grant
- 2019-04-16 HR HRP20190713TT patent/HRP20190713T1/hr unknown
- 2019-05-10 CY CY20191100510T patent/CY1121763T1/el unknown
- 2019-08-29 US US16/555,620 patent/US11001571B2/en active Active
-
2020
- 2020-02-17 AR ARP200100433A patent/AR118120A2/es unknown
- 2020-03-19 AU AU2020202000A patent/AU2020202000B2/en active Active
- 2020-10-06 JP JP2020168950A patent/JP7126741B2/ja active Active
-
2021
- 2021-01-22 CY CY20211100050T patent/CY1123756T1/el unknown
- 2021-01-22 HR HRP20210119TT patent/HRP20210119T1/hr unknown
- 2021-04-13 US US17/229,397 patent/US11591318B2/en active Active
- 2021-04-26 IL IL282644A patent/IL282644B/en unknown
- 2021-04-29 AU AU2021202685A patent/AU2021202685B2/en active Active
- 2021-10-17 IL IL287313A patent/IL287313B/en unknown
-
2022
- 2022-08-10 JP JP2022128042A patent/JP2022163162A/ja active Pending
- 2022-10-31 AU AU2022263454A patent/AU2022263454B2/en active Active
-
2023
- 2023-01-24 US US18/101,014 patent/US11905275B2/en active Active
-
2024
- 2024-01-02 US US18/402,493 patent/US12247020B2/en active Active
- 2024-05-15 JP JP2024079435A patent/JP2024105557A/ja active Pending
-
2025
- 2025-02-05 US US19/045,868 patent/US20250206726A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CR20150633A (es) | Derivados del bipirazol como inhibidores jak | |
| ECSP14013148A (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
| CO2017011851A2 (es) | Compuestos novedosos | |
| UY35898A (es) | ?compuestos inhibidores de syk y composiciones que los comprenden?. | |
| MX2020011774A (es) | Compuestos de naftiridina como inhibidores de quinasa jak. | |
| MX386935B (es) | Profármacos de fumaratos y su uso en el tratamiento de diferentes enfermedades. | |
| MX2019005232A (es) | Derivados de piperidin-4-il azetidina como inhibidores de janus cinasa 1 (jak1). | |
| BR112015009942A2 (pt) | derivados de tiofeno fundidos tricíclicos como inibidores de jak | |
| MX372997B (es) | Compuestos de aminopirimidina como inhibidores de jak. | |
| CU20160167A7 (es) | Compuestos de pirazolopiridinas y pirazolopirimidinas útiles en el tratamiento de condiciones alérgicas y respiratorias | |
| CU24187B1 (es) | Derivados sustituidos de imidazopiridazinas útiles para el tratamiento o profilaxis de trastornos hiperproliferativos y la angiogénesis | |
| MX371312B (es) | Pirazolil-ureas como inhibidores de quinasas. | |
| UY36285A (es) | Compuestos que inhiben la proteína mcl-1 | |
| NI201500176A (es) | Derivados de prodroga de triazolpiridinas sustituidas | |
| MY192305A (en) | Bipyrazole derivatives as jak inhibitors | |
| UA110978C2 (uk) | Азетидинілфенілові, піридилові або піразинілкарбоксамідні похідні як інгібітори jak | |
| ECSP15021681A (es) | Derivados tricíclicos fusionados de tiofeno como inhibidores de jak |